I've argued several times against an IPO.  Major dilution and I expect there would be tens of millions of shares looking for an exit.  ZHCLF tells me where the stock price would go.

There are multiple Zenith/NCI studies starting this year. As we saw earlier this week, the ZEN-3694 + KEYTRUDA trial won't end until the end of 2025 (which means 2026).  I assume the other studies to be announced will have similar timelines.

I don't see why any pharma would spend billions without seeing the results of those studies.  Yes, there will be some interim data, but I would expect them to wait to the conclusion of the studies.

I suppose there is some hope of deals based on the prostate and breast cancer studies (and continuing studies) before 2026.  Otherwise, I don't expect to see any $$$ in my pockets anytime soon.  DM sure gives the impression of a more optimistic timeline for unlocking shareholder value, so hopefully I've got it wrong.